Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 5188-5196

  Olmos, David ^a,b   Baird, Richard D ^a,b   Yap, Timothy A ^a,b   Massard, Christophe ^a,b   Pope, Lorna ^b   Sandhu, Shahneen K ^a,b   Attard, Gerhardt ^a,b   Dukes, Juliet ^b   Papadatos Pastos, Dionysis ^a   Grainger, Philippa ^b   Kaye, Stan B ^a,b   De Bono, Johann S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; LACTATE DEHYDROGENASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CELL COUNT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; SARCOMA; SCORING SYSTEM; STATISTICAL MODEL; UROGENITAL TRACT CANCER;

ADOLESCENT; ADULT; AGED; CELL COUNT; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79960975049     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3019     Document Type: Article

References (36)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000;18:684-92. (Pubitemid 30078550)
2. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-6.
3. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008;98:1029-33. (Pubitemid 351399798)
4. Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000;11:151-6. (Pubitemid 30148727)
5. Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 2003;89:1166-71. (Pubitemid 37363397)
6. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904. (Pubitemid 40300298)
7. Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 2008;19:787-92. (Pubitemid 351467383)
8. Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O'Brien S, Kut M, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994;74:1965-73. (Pubitemid 24301862)
9. Penel N, Vanseymortier M, Bonneterre ME, Clisant S, Dansin E, Vendel Y, et al. Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 2008;26:53-8.
10. Roberts TG, Jr., Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004;292:2130-40. (Pubitemid 39435104)
11. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, et al. Survival of patients in a phase I Clinic: the M. D. Anderson Cancer Center experience. Cancer 2009;115:1091-9.
12. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
13. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
14. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
15. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904. (Pubitemid 39383039)
16. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005;65:713-8. (Pubitemid 40523005)
17. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009;20:27-33.
18. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
19. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
20. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9. (Pubitemid 44799711)
21. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-9.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
23. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7. (Pubitemid 29517916)
24. Penel N, Delord JP, Bonneterre ME, Bachelot T, Ray-Coquard I, Blay JY, et al. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs 2010;28:76-82.
25. DeLong E, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
26. Vergara I, Norambuena T, Ferrada E, Slater A, Melo F. StAR: a simple tool for the statistical comparison of ROC curves. BMC Bioinformat 2008;9:265.
27. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 2008;44:1536-40.
28. Chen EX, Tannock IF. Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA 2004;292:2150-1. (Pubitemid 39435106)
29. Yamamoto N, Tamura T, Fukuoka M, Saijo N. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 1999;15:737-41.
30. Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, et al. A study of the pattern of hospital admissions in a specialist phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. Eur J Cancer 2010;46:2739-45.
31. Maestro LM, Sastre J, Rafael SB, Veganzones SB, Vidaurreta M, Martin M, et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res 2009;29:4839-43.
32. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
33. Frattini M, Balestra D, Verderio P, Gallino G, Leo E, Sozzi G, et al. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients. J Clin Oncol 2005;23:3163-4; author reply 4-5.
34. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
35. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
36. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13:3611-6. (Pubitemid 46955123)